![Michael Gray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Gray
Direttore Finanziario/CFO presso
UPSTREAM BIO, INC.
Patrimonio netto: 199 261 $ in data 30/06/2026
Profilo
Michael Paul Gray currently works at The American Institute of Certified Public Accountants, as Member and Upstream Bio, Inc., as Chief Financial & Operating Officer from 2024.
Mr. Gray also formerly worked at X4 Pharmaceuticals, Inc., as President, Chief Executive Officer & CFO from 2018 to 2019, Arsanis, Inc., as President, CEO, Chief Financial Officer & Director from 2018 to 2022, Therapeutics Acquisition Corp., as Independent Director from 2020 to 2021, Curis, Inc., as Secretary, Chief Financial & Business Officer from 2014 to 2016, Tetraphase Pharmaceuticals, Inc., as Chief Financial Officer & Senior Vice President, Reprogenesis, Inc., as Controller from 1998 to 2000, Enliven Therapeutics, Inc., as Chief Financial & Operating Officer from 2019 to 2023, Carmot Therapeutics, Inc., as Chief Operating & Financial Officer from 2023 to 2024, and Imara, Inc., as Chief Financial & Operating Officer from 2019 to 2023.
Mr. Gray received his undergraduate degree from Bryant University and Masters Business Admin degree from F.W.
Olin Graduate School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
UPSTREAM BIO, INC. 0,05% | 16/06/2026 | 28.795 ( 0,05% ) | 199 261 $ | 30/06/2026 |
Posizioni attive di Michael Gray
| Società | Posizione | Inizio |
|---|---|---|
| UPSTREAM BIO, INC. | Direttore Finanziario/CFO | 01/03/2024 |
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Corporate Officer/Principal | - |
Precedenti posizioni note di Michael Gray
| Società | Posizione | Fine |
|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Direttore Finanziario/CFO | 01/02/2024 |
| IMARA | Direttore Finanziario/CFO | 01/03/2023 |
| ENLIVEN THERAPEUTICS, INC. | Direttore Finanziario/CFO | 23/02/2023 |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Amministratore Delegato | 01/03/2022 |
| THES ACQU | Direttore/Membro del Consiglio | 01/07/2021 |
Formazione di Michael Gray
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
56
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Curis, Inc.
 Curis, Inc. BiotechnologyHealth Technology Develops therapeutics to treat cancer | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services Association of accountants | Commercial Services |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Produces products in urology, cardiovascular biology, plastic, and reconstructive surgery | Health Technology |
Bryant University
 Bryant University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops drugs for inflammatory, metabolic and neurological diseases | Health Technology |
F.W. Olin Graduate School of Business
 F.W. Olin Graduate School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
X4 Pharmaceuticals, Inc.
 X4 Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which engages in developing human antibodies for treating infectious diseases | Health Technology |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Upstream Bio, Inc.
 Upstream Bio, Inc. BiotechnologyHealth Technology Engages in developing treatments for inflammatory diseases | Health Technology |
Enliven Therapeutics, Inc.
 Enliven Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage precision oncology company that develops molecule therapies | Health Technology |
